The First Truly

Non-Invasive

Glucose Monitor

© 2017 Feb Integrity Applications. All Rights Reserved

Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995 and various provisions of the U.S. Securities Act of 1933, as amended, and

the U.S. Securities Exchange Act of 1934, as amended. All statements, other than statements of historical

facts, included in this presentation are forward-looking statements. Forward-looking statements included in

this presentation address, among other things, our future product development activities, strategies and

timing of seeking regulatory approval to market our current product candidate. These statements are

based on certain historical trends, current conditions and expected future developments as well as other

factors the Company believes are appropriate in the circumstances. In addition to statements which

explicitly describe these risks and uncertainties, readers are urged to consider statements labeled with the

terms “expects”, “anticipates” and other similar words and phrases to be uncertain and forward-looking. All

of the forward-looking statements made in this presentation are qualified by these cautionary statements

and there can be no assurance that the actual results anticipated by the Company will be realized or, even

if substantially realized, that they will have the expected consequences to or effects on the Company or its

business or operations. Whether actual results will conform to the Company’s expectations and predictions

is subject to a number of risks and uncertainties that may cause actual results to differ materially. See the

risks described in our reports filed with the Securities and Exchange Commission, including under the

heading "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2015.

Dedicated to the development and commercialization of

innovative needle free and pain free glucose monitoring

Integrity Applications

Company Overview

Proven

Technology

>13 years of

development and trials

> 820 subjects

Patent-protected unique

approach

Simple to use

High reliability

Compelling economics

<30 minute calibration

once every six months

GlucoTrack®

for Type 2 &

Pre-Diabetic

Users

Commercial

Stage

Regulatory approvals by

CE Mark; South-Korea

Commercialization with

distributors underway

US FDA trials expected

to commence in 2017

The Diabetes Epidemic

Source: International Diabetes Foundation Diabetes Atlas, 7th Edition, 2015

2015: 415 million people diagnosed with diabetes

2040: 642 million people diagnosed with diabetes

Prevelance: 10% of the Global Adult Population (2015)

One in 11 adults has diabetes (415 million)

One in 15 adults has impaired glucose tolerance (318 million)

Source: International Diabetes Foundation Diabetes Atlas, 7th Edition, 2015

One in 2 adults with diabetes is Undiagnosed (193 million)

$673 Billion spent annually - 12% of global health expense

Challenges with Conventional Self Monitoring of

Blood Glucose (SMBG)

Vast majority of diabetics (Type 2) don’t test

at all or often enough

Invasive and inconvenient

• Patient pain and fear

• Social stigma

Expensive

• Insurance covers a minimal test regimen

Risk of decreased accuracy due to human

factors

• Unwashed hands

• Strip degradation

• Patient error $11B Global Market (2014)

Source: P&S Market Research, 2015

Frequent Glucose Monitoring is Essential to

Manage Diabetes

Source: The American Journal of Medicine, Vol. 111, July 2001

More Frequent Glucose Monitoring Leads to

Better Glycemic Control

CONCLUSION

More frequent self-

monitoring showed better

glycemic control, regardless

of diabetes type or therapy

Study of over 24,000 adults with diabetes

Challenges with a Non-Invasive Approach

Accuracy issues (indirect and non-specific)

“Noise” (“internal” and “external”)

Calibration (duration, # of pricking, validity)

Lag time (ISF/tissue, blood)

Usability (ease of use, comfort, human factors)

General skepticism

GlucoTrack® Model DF-F a Commercial-Stage, Non-Invasive Solution

GlucoTrack® Model DF-F

Personal Ear Clip

(PEC)

replaced every 6 months

Main Unit

(MU)

GlucoTrack® Unique Approach

Three independent (non-optical)

technologies

Patented combination

• Ultrasound

• Electromagnetic (conductivity)

• Thermal (heat capacity)

Compensation for ambient temperature

Provides prospective, real-time reading

of glucose level in about one minute

GlucoTrack® Calibration

HOW MANY?

HOW LONG?

HOW OFTEN?

THREE (individual data set)

LESS THAN 30 MINUTES (10 min. interval)

ONCE EVERY 6 MONTHS (with new ear clip)

Simple, Less Than 30 Minutes, Once Every Six Months

Users Response

"GlucoTrack® provides

a much more

comfortable diabetes

tracking, compared

with blood glucose

testing.” Luis, Centro de Especialidades José

Marvá. Madrid. May, 4, 2016. T2 with

basal insulin

“I have no doubts

GlucoTrack® has a

positive impact on

the quality of my

life.” Matías, Hospital Virgen Macarena.

Seville. March, 25, 2016. T2 with

IDPP IV + Metformin

“If I analyzed more frequently I'd be

better controlled. So I am testing

more often now because there is no

hassle involved.” Antonio, Centro de Especialidades José Marvá. Madrid.

May, 4, 2016. T2 with IDPP IV + Metformin

“I am sure that the availability of the

measurements without pricking,

assisted me in reducing my A1C levels

to 5.6%!” Dr. Aharon, 65, type 2 diabetes, diagnosed 20 years ago,

Israel, January 2017.

Commercialization Opportunity in Approved

Markets (~31M Potential Users)

Launching with 15 Distributors in Approved Markets

US FDA Trials Expected

to Commence in 2017

The territories in which GlucoTrack® has been approved for sale currently represent a

potential market opportunity of about 20 million diagnosed Type 2 diabetics, and 11 million

people who are pre-diabetic

Competitive Landscape (Type 1, Type 2 & Pre-Diabetes)

Stage of Development

Ad

dre

ssa

ble

Ma

rke

t S

ize

Development Commercial

Sm

all

La

rge

GlucoWise, UK

Google Lens, USA Echo Therapeutics, USA

GlucoTrack, Israel

Cynoga, Israel

Abbott Libre, USA

Scalable Manufacturing Strategy

Contract manufacturing partners

• AY Electronics (Israel)

oA few thousand devices manufactured to date

• Wistron Corporation

oTaiwan, manufacturing arm of Acer Computers

oCapable of high volume manufacturing

oTaiwan FDA (TFDA) Good Manufacturing Practice (GMP) audit

successfully completed

Management Team Avner Gal: President & CEO,

Chairman (Co-Founder) • Served as development engineer to initialize

and execute Electronic Warfare combat suite

on board the fleet of the Israeli Navy ships

• Executive in the fields of engineering,

technology, and intelligence systems

Eran Cohen: COO • Over 17 years of extensive and diversified

experience in global executive roles in

variety of high-tech and bio-med companies

• Domestic and overseas operational

experience

CCO

• Search underway

Sami Sassoun: CFO • Extensive experience in corporate finance, fund-

raising, financial controls, operations, audit,

accounting and investor relations

• Experienced in public accounting, and growth-stage

companies

• Certified Public Accountant in (CPA) USA

Ron Roobroeck: Director of Int’l

Marketing & Sales • Over 20 years of international experience of

marketing, sales and business development

• Prior experience: Novartis, Roche, Medtronic,

Cyberonics and Terumo

Boudewijn Baks: Int’l Sales Manager • Over 25 years of international experience of

marketing, sales and management

• Prior experience: Merck, Pfizer, Abbott Diabetes

Care

Scientific Advisory Board

Prof. Dr. Lutz Heinemann (Chairman): CEO, Science & Co,

Düsseldorf, Germany

Prof. Irl B. Hirsch: University of Washington, School of Medicine,

WA, USA

Prof. Dr. Michael Heise: University of Applied Science of South-

Westphalia, Iserlohn, Germany

Prof. Jan Bolinder: Professor of Clinical Diabetes Research at the

Department of Medicine, Huddinge, Sweden

Prof. Katharine Barnard: Health Psychologist, Bournemouth

University, Faculty of Health and Social Science, England

Dr. Barry H. Ginsberg: Diabetes Consultant, DMTC, NJ, USA

Independent Directors Philip M. Darivoff: Chairman of the Board of DFG Investment Advisers and

Vibrant Capital Partners, LLC. Former managing director of Goldman Sachs.

Dr. Robert Fischell: Inventor of more than 200 issued patents and founder of

multiple companies that have been licensed or acquired by more than 14

organizations. Inventor of the first implanted insulin pump (acquired by MDT).

Angela Strand: Founder and senior executive of Nohm; Founder of Strand

Strategy; Founder and CEO of Cliffdive Records. Former executive with multiple

biotech and digital health companies in diabetes and metabolic disease.

Les Seff: Founder and chief operating officer of AIMPaaS LLC; Founder and

president of Matthew B. Management, Inc. Previously built and ran the NASDAQ

trading department at Fidelity Investments.

Revan R. Schwartz, Esq.: Attorney in private practice. Previously Executive Vice

President and General Counsel for Andrew Garrett, Inc.

Investor Summary Proven Technology, Unique Approach

GlucoTrack® Commercialization Underway in Variety of Locations

GlucoTrack® US FDA Trials Expected to Commence in 2017

Building World-Class Commercialization Team

Stock Data (as of January 2017)

Total capital invested: ~$34.9M

Common shares outstanding: 6.0M

Common shares underlying preferred: 4.8M

Total common shares outstanding (with preferred conversion): 10.8M

Your track to health!...™

Thank You!

www.integrity-app.com

© 2017 Feb Integrity Applications. All Rights Reserved